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approval for new devices for coronary and peripheral revas-
cularization was a necessary and sufficient requisite for
reimbursement from the Centers for Medicare and Medic-
aid Services (CMS). However, in the new millennium,
FDA approval is necessary, but not sufficient, for CMS
reimbursement, an issue that has become strikingly apparent
with regard to carotid artery stenting (CAS). Under the
current national coverage determination (NCD) policy,
there is CMS payment for CAS in symptomatic patients
with carotid stenosis 70% who are high risk for carotid
endarterectomy (CEA), using FDA-approved CAS systems
in CMS-approved institutions. The NCD policy requires
the use of approved embolic protection devices (EPD) (no
payment if an EPD is not used), predefined criteria for
performance of CAS procedures that are consistent with
professional societal guidelines, and independent neurolog-
ical assessment. The NCD policy also allows payment for
high-risk patients who are enrolled in Category B Investi-
gational Device Exemption (IDE) trials or post-approval
registries, as long as patients have symptomatic stenosis
50% or asymptomatic stenosis 80%. The NCD policy
does not cover CAS in any standard-risk patients; there are
no restrictions for CEA reimbursement.
See page 1383
In this issue of the Journal, Bijuklic et al. (1) performed a
small randomized clinical trial (RCT) that demonstrated
that CAS with proximal EPD provides better cerebral
protection than distal EPD, based on quantitative brain
diffusion-weighted magnetic resonance imaging. Although
the study was not powered to evaluate the risk of stroke, the
findings are similar to another RCT, which reported less
cerebral embolization by transcranial Doppler with proximal
EPD compared with distal EPD (2). These data are
sensible, since in contrast to distal EPDs, proximal EPDs
provide embolic protection prior to crossing the target lesion
*Editorials published in the Journal of the American College of Cardiology reflect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the Department of Cardiovascular Medicine, Beaumont Health System,
Royal Oak, Michigan. Dr. Safian has reported that he has no relationships relevant to
the contents of this paper to disclose.with a guidewire, and should be more efficient at capturing and
removing debris since they are not dependent on filter pore size
or particle dimensions. The findings of both studies add
further incremental understanding of CAS technique, but are
they likely to influence CMS reimbursement?
The lack of equipoise in CMS payment for CEA and
CAS is influenced by several factors. Professional societies
insist on adherence to the American Heart Association/
American Stroke Association benchmarks of 3% and 6% for
the 30-day risk of death and stroke for asymptomatic and
symptomatic patients, respectively (3). Some experts suggest
that European RCTs of CEA and CAS showed unequiv-
ocal superiority of CEA (4–6). However, these trials are
invalid by today’s standards of operator experience, dual
antiplatelet therapy, and EPDs, and did not meet CMS
NCD standards. Others refute the conclusions of the
CREST (Carotid Revascularization Endarterectomy versus
Stenting Trial) (7), arguing that equivalence of CEA and
CAS should not be based on a composite endpoint of death,
stroke, and myocardial infarction (MI) at 30 days. Finally,
many physicians express sentiments that patients with
asymptomatic carotid stenosis should be treated with opti-
mal medical therapy alone, even though optimal therapy has
not been defined, and the impact on patients with carotid
stenosis has not been studied.
Because 70% of CAS procedures are performed by
interventional cardiologists, there is concern among our
professional societies that some physicians advocate against
expansion of CMS coverage to protect their turf. In the
minds of advocates for expansion of coverage, this political
viewpoint seems to be supported by the failure of CMS to
modify its NCD policy, despite mounting evidence to do so.
Is it not reasonable for CMS to reconsider its NCD policy
since there is nearly a decade of CAS experience performed
in accordance with societal guidelines and CMS NCD
policy?
So, what is this evidence and where do we begin? There
is a historical divide in CAS studies in the United States
before and after the SAPPHIRE (Stenting and Angioplasty
with Protection in Patients at High Risk for Endarterec-
tomy) trial, which set important standards for the definition
of high-risk and standard-risk patients; routine use of EPD
and dual antiplatelet therapy; and independent neurological
assessment, data collection, and data analysis (8). In aggre-
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data in more than 5,000 high-risk and 2,000 standard-risk
patients. In SAPPHIRE, there was a strong trend favoring
the safety of CAS in high-risk patients by virtue of a lower
risk of major adverse cardiovascular events (MACE) at 30
days (death, stroke, MI) (8); outcomes for CAS and CEA
were similar at 3 years (9). In the high-risk IDE and registry
studies, there has been a dramatic decline in 30-day MACE
from 8% in the early experience to 2% in recent
experience (Fig. 1) (10). In standard-risk patients in
CREST, 30-day MACE was similar; significant differences
at 30 days included a higher risk of minor stroke after CAS,
a higher risk of MI after CEA, and a higher risk of cranial
nerve injury after CEA (7). Although differences in secondary
endpoints have ignited more debate about CEA and CAS, the
following points are crucial: First, event-free survival at 4 years
was 95% in both groups, consistent with superb outcomes;
second, 30-day MACE was similar for CEA and CAS in
symptomatic and asymptomatic patients; and third, there were
no major strokes or deaths at 30 days after CAS in the last 2
years of enrollment (W. Gray, personal communication, No-
vember 2011).
Taken together, it appears that current CAS outcomes in
all patients satisfy the American Heart Association/
American Stroke Association benchmarks. When consider-
ing central and cranial nerve injury, CAS is at least as safe
as CEA, and the risk of MI is lower after CAS. The
continued decline in 30-day MACE after CAS is attribut-
able to improvements in technology, technique, patient
selection, and operator experience, including the use of
Figure 1 MACE at 30 Days After CAS in High-Risk Studies
See Safian (10) for study eponyms and citations. The EMPIRE (Embolic Protec-
tion with Reverse Flow), ARMOUR (ProximAl PRotection with the MOMA Device
DUring CaRotid Stenting), and MoMa studies utilized proximal embolic protec-
tion, whereas other studies utilized distal embolic protection. CAS  carotid
artery stenting; MACE  major adverse cardiovascular events.proximal EPDs; imaging studies suggest less intracranialembolization with proximal EPDs than distal EPDs, al-
though the risk of stroke is low with both techniques.
Carotid revascularization for symptomatic stenosis 50%
nd asymptomatic stenosis 70% is the current standard of
are according to major professional societies, and is safely
erformed by CEA and CAS (3); further CAS trials are not
eeded to support reimbursement. It is time for CMS to
lign with professional guidelines, and establish equipoise
or CEA and CAS.
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